Adrian Rawcliffe, CEO of Adaptimmune at EUBIO22 (Photographer: Rachel Kiki)
November 8, 2022 11:02 AM EST
People

Adap­ti­m­mune trims pipeline, un­veils plans to lay off 25%+ of em­ploy­ees amid sweet­ened ES­MO da­ta

Paul Schloesser

Associate Editor

Adap­ti­m­mune has a bit­ter pill to swal­low af­ter GSK axed its part­ner­ship in late Oc­to­ber, com­ing in the form of a re­or­ga­ni­za­tion and bud­get cuts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times